Abstract YO14
Case summary
Urachal cancer is a rare neoplasm which represents approximately 0.5-2% of all bladder cancer.
A 52 year old Filipino male presented with painless hematuria. Physical examination was unremarkable. KUB ultrasound showed a bladder mass so Cystoscopy–TUR was done. Histopathology revealed adenocarcinoma with involvement of muscularis propria. He was advised surgery but did not consent. Contrast-enhanced abdominal computed tomography (CT) showed a well-defined, slightly wall enhancing, midline infraumbilical complex soft tissue mass measuring 3.6x4.0x5.1cm in the anterosuperior aspect of the urinary bladder extending to the urachus with no communication to the umbilicus. Cystoscopy, Partial Cystectomy with Umbilectomy was done. Intra-operative findings: bladder mass at the dome approximately 2-3cm in size, necrotic tissue with band of tissue directly connected to the umbilicus. Histopathology was urachal adenocarcinoma which extends to the urinary bladder muscularis propria and perivesical tissue. He was advised close follow-up.
After one year, he started to experience difficulty initiating urine. Repeat CT scan showed: urinary bladder with an intraluminal enhancing nodule in the superoanterior wall measuring 1.5x1.7cm, irregular anterior urinary bladder wall thickening measuring 7.3x1.5cm is also noted, small anterior perivesical nodes are noted measuring 0.7x1.2 cm. Cysto-TURP of Bladder Tumor, Exploratory Laparotomy, Adhesiolysis, was done. Intra-operative findings were: smooth urethral mucosa without stenosis or stricture; pedunculated broad-based, friable, pink fleshy mass seen at the posterolateral bladder wall, measuring 5-8 cm in greatest diameter; flat erythematous lesion measuring 2cm noted at bladder dome; muiltiple nodularities along peritoneum with some attached to ileal loops. Specimen’s pathology reported adenocarcinoma and peritoneal nodularities were metastatic adenocarcinoma; morphological features favored the diagnosis of urachal adenocarcinoma. CT scan of the Chest showed innumerable varisized non-calcified parenchymal, fissural, and subpleural nodules scattered in both lungs which were worrisome for metastasis. The patient has received systemic chemotherapy with Cisplatin and Fluorouracil.
Clinical trial identification
Editorial acknowledgement
Resources from the same session
518P - Real world prospective clinical impact of finding actionable genomic alterations by plasma cell-free DNA next generation sequencing in advanced non-small cell lung cancer
Presenter: Beung chul Ahn
Session: Poster display session
Resources:
Abstract
508P - Efficacy and safety of anti-PD-1 antibody SHR-1210 combined with apatinib in first-line treatment for advanced lung squamous carcinoma: A phase II study
Presenter: Jinliang Wang
Session: Poster display session
Resources:
Abstract
525P - Retrospective analysis of outcomes of cisplatin and irinotecan combination chemotherapy for unresectable thymic carcinoma
Presenter: Akito Fukuda
Session: Poster display session
Resources:
Abstract
524P - A study in recurrent small cell lung cancer patients, comparing weekly paclitaxel, irinotecan and temozolomide in second-line: A prospective study from a south Indian tertiary cancer hospital
Presenter: LALATENDU MOHARANA
Session: Poster display session
Resources:
Abstract
505P - PD-L1 expression in ALK rearranged NSCLC: All questions answered?
Presenter: Amrith B P
Session: Poster display session
Resources:
Abstract
487P - Afatinib versus gefitinib or erlotinib in first-line setting for Malaysia patients with EGFR mutant advanced lung adenocarcinoma
Presenter: Chee Shee Chai
Session: Poster display session
Resources:
Abstract
492P - Feasibility of rebiopsy and sequential treatment of EGFR tyrosine kinase inhibitors in real world patients with EGFR mutant non-small cell lung cancer
Presenter: Heekyung Ahn
Session: Poster display session
Resources:
Abstract
513P - Phase II study of vitamin B12 and folate supplementation for patients undergoing chemotherapy with pemetrexed
Presenter: Shingo Kitagawa
Session: Poster display session
Resources:
Abstract
493P - Is exon 19 deletion different from exon 21 mutation in advanced non-small cell lung cancer: A single centre experience
Presenter: Sarita Shrivastva
Session: Poster display session
Resources:
Abstract
494P - Comparison of pattern of disease progression and prevalence of acquired T790M mutation in Malaysia patients with EGFR mutant lung adenocarcinoma upon failure of first-line afatinib, gefitinib and erlotinib
Presenter: Chee Shee Chai
Session: Poster display session
Resources:
Abstract